爱博医疗(688050) - 2025 Q4 - 年度业绩

Financial Performance - The total revenue for 2025 reached CNY 148,270.27 million, representing a year-on-year increase of 5.15%[2] - The net profit attributable to the parent company was CNY 26,541.48 million, a decrease of 31.67% compared to the previous year[6] - The net profit excluding non-recurring gains and losses was CNY 25,311.33 million, down 35.11% year-on-year[6] - Operating profit decreased by 33.04% to CNY 28,993.91 million[10] - The basic earnings per share decreased by 32.68% to CNY 1.38[2] Asset and Equity - The company's total assets increased by 11.01% to CNY 388,198.73 million compared to the beginning of the period[7] - The equity attributable to the parent company rose by 15.62% to CNY 278,597.73 million[7] Asset Impairment - The company recognized an asset impairment loss of CNY 8,669.29 million, primarily related to goodwill and fixed assets in the contact lens business[8] Return on Investment - The weighted average return on net assets fell by 7.27 percentage points to 10.05%[2] Cash Flow - Cash flow from operating activities increased by 4.22%, providing support for the company's ongoing development[5]